- Home
- SACH vs ONCY Comparison
SACH vs ONCY Comparison
Compare SACH & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- ONCY
- Stock Information
- Founded
- SACH 2010
- ONCY 1998
- Country
- SACH United States
- ONCY Canada
- Employees
- SACH N/A
- ONCY N/A
- Industry
- SACH Real Estate Investment Trusts
- ONCY Pharmaceuticals and Biotechnology
- Sector
- SACH Real Estate
- ONCY Health Care
- Exchange
- SACH Nasdaq
- ONCY Nasdaq
- Market Cap
- SACH 60.6M
- ONCY 61.0M
- IPO Year
- SACH 2017
- ONCY 1999
- Fundamental
- Price
- SACH $1.24
- ONCY $0.78
- Analyst Decision
- SACH Buy
- ONCY Strong Buy
- Analyst Count
- SACH 2
- ONCY 2
- Target Price
- SACH $2.25
- ONCY $4.00
- AVG Volume (30 Days)
- SACH 518.7K
- ONCY 2.6M
- Earning Date
- SACH 11-14-2024
- ONCY 03-06-2025
- Dividend Yield
- SACH 19.51%
- ONCY N/A
- EPS Growth
- SACH N/A
- ONCY N/A
- EPS
- SACH N/A
- ONCY N/A
- Revenue
- SACH $10,951,064.00
- ONCY N/A
- Revenue This Year
- SACH N/A
- ONCY N/A
- Revenue Next Year
- SACH N/A
- ONCY N/A
- P/E Ratio
- SACH N/A
- ONCY N/A
- Revenue Growth
- SACH N/A
- ONCY N/A
- 52 Week Low
- SACH $1.11
- ONCY $0.71
- 52 Week High
- SACH $4.64
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- SACH 45.51
- ONCY 42.70
- Support Level
- SACH $1.20
- ONCY $0.73
- Resistance Level
- SACH $1.30
- ONCY $0.86
- Average True Range (ATR)
- SACH 0.08
- ONCY 0.06
- MACD
- SACH 0.02
- ONCY -0.00
- Stochastic Oscillator
- SACH 41.38
- ONCY 33.08
About SACH Sachem Capital Corp.
Sachem Capital Corp is a United States-based real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.